Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FOLD | US
-0.01
-0.07%
Healthcare
Biotechnology
30/06/2024
10/03/2026
14.36
14.34
14.36
14.34
Amicus Therapeutics Inc. a biotechnology company focuses on discovering developing and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia Pennsylvania.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Midcap (2B - 10B USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
2.2%1 month
2.0%3 months
62.4%6 months
50.4%-
53.19
26.63
3.35
0.59
-35.99
8.15
-0.18
-16.68M
4.26B
4.26B
-
11.82
-
34.00
-97.94
9.99
7.37
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.05
Range1M
0.09
Range3M
4.66
Rel. volume
0.83
Price X volume
47.68M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | XENE | Biotechnology | 60.61 | 4.59B | -3.43% | n/a | 1.19% |
| Alkermes plc | ALKS | Biotechnology | 27.74 | 4.57B | -2.50% | 12.40 | 28.66% |
| TG Therapeutics Inc | TGTX | Biotechnology | 29.27 | 4.53B | 0.27% | 34.28 | 63.38% |
| CRISPR Therapeutics AG | CRSP | Biotechnology | 52.8 | 4.50B | -10.17% | n/a | 11.68% |
| Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 90.93 | 4.34B | 2.42% | n/a | 138.24% |
| Erasca Inc. Common Stock | ERAS | Biotechnology | 15.58 | 4.24B | -1.14% | n/a | 11.96% |
| Scholar Rock Holding Corporation | SRRK | Biotechnology | 44.78 | 4.04B | 1.24% | n/a | 50.92% |
| Fluent Inc | COGT | Biotechnology | 36.68 | 4.01B | -0.89% | n/a | 4.87% |
| Ligand Pharmaceuticals Incorporated | LGND | Biotechnology | 212.29 | 3.88B | 1.98% | 45.66 | 0.98% |
| Viking Therapeutics Inc | VKTX | Biotechnology | 34.66 | 3.84B | 3.12% | n/a | 0.12% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Thor Industries Inc | THO | Recreational Vehicles | 84.71 | 4.48B | -1.37% | 23.44 | 27.88% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 26.02 | 3.24B | 0.93% | 102.46 | 2.10% |
| LCI Industries | LCII | Recreational Vehicles | 126.52 | 3.22B | -1.75% | 25.82 | 77.66% |
| Polaris Industries Inc | PII | Recreational Vehicles | 52.75 | 2.94B | 0.04% | 14.48 | 170.51% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 18.91 | 2.49B | 0.75% | 7.33 | 218.58% |
| HNI Corporation | HNI | Building Products & Equipment | 40.43 | 1.91B | -2.27% | 22.12 | 76.47% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 10.59 | 1.90B | -0.75% | n/a | -571.93% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.8 | 1.38B | -1.92% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.32 | 1.14B | 0.28% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 34.15 | 988.81M | -3.12% | 22.53 | 56.33% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -35.99 | 0.53 | Cheaper |
| Ent. to Revenue | 8.15 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 26.63 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 62.37 | 72.80 | Par |
| Debt to Equity | 3.35 | -1.23 | Expensive |
| Debt to Assets | 0.59 | 0.25 | Expensive |
| Market Cap | 4.26B | 3.66B | Par |